Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity

Huabin Zhu, Henrique Lemos, Brinda Bhatt, Bianca N. Islam, Abhijit Singh, Ashish Gurav, Lei Huang, Darren D. Browning, Andrew Mellor, Sadanand Fulzele, Nagendra Singh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson’s Disease (PD). PD is associated with increased expression of inflammatory genes in peripheral and central nervous system (CNS), infiltration of immune cells into brain, and increased numbers of activated/memory T cells. Animal models of PD have shown a critical role of T cells in inducing pathology in CNS. However, the effect of carbidopa on T cell responses in vivo is unknown. In this report, we show that carbidopa strongly inhibited T cell activation in vitro and in vivo. Accordingly, carbidopa mitigated myelin oligodendrocyte glycoprotein peptide fragment 35–55 (MOG-35-55) induced experimental autoimmune encephalitis (EAE) and collagen induced arthritis in animal models. The data presented here suggest that in addition to blocking peripheral conversion of levodopa, carbidopa may inhibit T cell responses in PD individuals and implicate a potential therapeutic use of carbidopa in suppression of T cell mediated pathologies.

Original languageEnglish (US)
Article numbere0183484
JournalPloS one
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Carbidopa
autoimmunity
T-cells
Parkinson disease
Autoimmunity
Parkinson Disease
T-lymphocytes
Chemical activation
Neurology
L-dopa
T-Lymphocytes
drugs
central nervous system
Central Nervous System
Pharmaceutical Preparations
Levodopa
Pathology
Animals
Animal Models
animal models

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. / Zhu, Huabin; Lemos, Henrique; Bhatt, Brinda; Islam, Bianca N.; Singh, Abhijit; Gurav, Ashish; Huang, Lei; Browning, Darren D.; Mellor, Andrew; Fulzele, Sadanand; Singh, Nagendra.

In: PloS one, Vol. 12, No. 9, e0183484, 01.09.2017.

Research output: Contribution to journalArticle

Zhu, Huabin ; Lemos, Henrique ; Bhatt, Brinda ; Islam, Bianca N. ; Singh, Abhijit ; Gurav, Ashish ; Huang, Lei ; Browning, Darren D. ; Mellor, Andrew ; Fulzele, Sadanand ; Singh, Nagendra. / Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. In: PloS one. 2017 ; Vol. 12, No. 9.
@article{dfa130351c754c4ca61c67afb50c9a55,
title = "Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity",
abstract = "Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson’s Disease (PD). PD is associated with increased expression of inflammatory genes in peripheral and central nervous system (CNS), infiltration of immune cells into brain, and increased numbers of activated/memory T cells. Animal models of PD have shown a critical role of T cells in inducing pathology in CNS. However, the effect of carbidopa on T cell responses in vivo is unknown. In this report, we show that carbidopa strongly inhibited T cell activation in vitro and in vivo. Accordingly, carbidopa mitigated myelin oligodendrocyte glycoprotein peptide fragment 35–55 (MOG-35-55) induced experimental autoimmune encephalitis (EAE) and collagen induced arthritis in animal models. The data presented here suggest that in addition to blocking peripheral conversion of levodopa, carbidopa may inhibit T cell responses in PD individuals and implicate a potential therapeutic use of carbidopa in suppression of T cell mediated pathologies.",
author = "Huabin Zhu and Henrique Lemos and Brinda Bhatt and Islam, {Bianca N.} and Abhijit Singh and Ashish Gurav and Lei Huang and Browning, {Darren D.} and Andrew Mellor and Sadanand Fulzele and Nagendra Singh",
year = "2017",
month = "9",
day = "1",
doi = "10.1371/journal.pone.0183484",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity

AU - Zhu, Huabin

AU - Lemos, Henrique

AU - Bhatt, Brinda

AU - Islam, Bianca N.

AU - Singh, Abhijit

AU - Gurav, Ashish

AU - Huang, Lei

AU - Browning, Darren D.

AU - Mellor, Andrew

AU - Fulzele, Sadanand

AU - Singh, Nagendra

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson’s Disease (PD). PD is associated with increased expression of inflammatory genes in peripheral and central nervous system (CNS), infiltration of immune cells into brain, and increased numbers of activated/memory T cells. Animal models of PD have shown a critical role of T cells in inducing pathology in CNS. However, the effect of carbidopa on T cell responses in vivo is unknown. In this report, we show that carbidopa strongly inhibited T cell activation in vitro and in vivo. Accordingly, carbidopa mitigated myelin oligodendrocyte glycoprotein peptide fragment 35–55 (MOG-35-55) induced experimental autoimmune encephalitis (EAE) and collagen induced arthritis in animal models. The data presented here suggest that in addition to blocking peripheral conversion of levodopa, carbidopa may inhibit T cell responses in PD individuals and implicate a potential therapeutic use of carbidopa in suppression of T cell mediated pathologies.

AB - Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson’s Disease (PD). PD is associated with increased expression of inflammatory genes in peripheral and central nervous system (CNS), infiltration of immune cells into brain, and increased numbers of activated/memory T cells. Animal models of PD have shown a critical role of T cells in inducing pathology in CNS. However, the effect of carbidopa on T cell responses in vivo is unknown. In this report, we show that carbidopa strongly inhibited T cell activation in vitro and in vivo. Accordingly, carbidopa mitigated myelin oligodendrocyte glycoprotein peptide fragment 35–55 (MOG-35-55) induced experimental autoimmune encephalitis (EAE) and collagen induced arthritis in animal models. The data presented here suggest that in addition to blocking peripheral conversion of levodopa, carbidopa may inhibit T cell responses in PD individuals and implicate a potential therapeutic use of carbidopa in suppression of T cell mediated pathologies.

UR - http://www.scopus.com/inward/record.url?scp=85029371761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029371761&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0183484

DO - 10.1371/journal.pone.0183484

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0183484

ER -